All News

knee.injx_.lat_.jpg

EULAR Guidelines on Intraarticular Therapy

d Jack Cush, MD

EULAR has published evidence-based recommendations on the use of intra-articular therapies (IAT) based on the literature review and recommendations of a multidisciplinary international task force. These IAT recommendations apply to adult patients with peripheral arthropathies.

Read Article
pills-3d-render-5-1165365.jpg

Triple DMARD Therapy Bested by Biologics in Swedish Registry

d Jack Cush, MD

The Swedish Register compared outcomes of 1502 rheumatoid arthritis (RA) patients initiating either biologics plus methotrexate (MTX) or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) and showed similar rates of sustained remission.

Read Article
CV,risk,MI,heart,cardiac

CV Risk Decreased with Certain DMARDs in Rheumatoid Arthritis

d Jack Cush, MD

A large prospective cohort study examined the comparative risks of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA) and found that, methotrexate (MTX), abatacept (ABA) and TNF inhibitor (TNFi) use were associated with a decreased risk of CV events. 

Read Article
Covid lung pneumonia corona (keep)

Tocilizumab Augmented Efficacy in COVID-19 Pneumonia with High CRP

d Jack Cush, MD

JAMA Internal Medicine report an analysis of recent and composite trial data suggesting that tocilizumab (TCZ) therapy in COVID-19–associated pneumonia patients with high CRP levels is likely to be effective.

Read Article
healthcare.costs_.jpg

Congress Slams AbbVie Over Price Hikes, 'Frivolous' Patents

d MedPage Today

House lawmakers on both sides of the aisle pummeled AbbVie CEO Richard Gonzalez for raising the price of two widely used drugs and for the company's "legally questionable" tactics to head off competition from biosimilars, despite pulling in healthy profits.

Read Article
News Feature: CV Risk Decreased with Certain DMARDs in Rheumatoid Arthritis A large prospective cohort study examined the comparative risks of CVD in patients with RA and found that, MTX, ABA & TNFi use were associated w/ a decreased risk of CV events. https://t.co/uQbtB76Hgy https://t.co/ftc5ys9C58

Links:

Dr. John Cush RheumNow ( View Tweet)
Mark your calendars--we'll be covering EULAR 2021 from June 3 through June 8. Over coverage will include new articles, videos, polls and more. https://t.co/LksbsK2TW2
Dr. John Cush RheumNow ( View Tweet)
Interesting report of 27 pts w/ Jo-1 anti-synthetase syndrome shows that only 4 had classic triad at presentation. 7 patients presented with polyarthritis, 6/7 initially Dx as #RA, Time gap from RA to antisynthetase dx was 3 to 20 years. https://t.co/IMgk3VTr0c

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Samir V. Parikh from the #SLEEducatorsNetwork discusses the major treatment goals for lupus nephritis and the broader needs of the patient in this program- Defining Treatment Goals for Lupus Nephritis. Sponsored by GSK US Medical Affairs https://t.co/f2Y707YDJr https://t.co/lsYDVFWSCS

Links:

Dr. John Cush RheumNow ( View Tweet)
Good Free 2 part series on Juvenile Fibromyalgia: a chronic diffuse musculoskeletal aching and pain syndrome that may be hard to distinguish from complex regional pain syndrome (CRPS) (ALWAYS CHECK FOR HYPERMOBILITY in Kids) https://t.co/EPmmGVNW63 https://t.co/aP6QHT7tiM

Links:

Dr. John Cush RheumNow ( View Tweet)

Preliminary results from 600 pt SAVE-MORE trial in severe COVID, anakinra + standard-of-care was 55% better than SOC in preventing death or respiratory failure; and improving Hosp Discharge by 4 days. Anakinra Rx 100mg/day up to 10 days https://t.co/vbpUMQjC1o

Links:

Dr. John Cush RheumNow ( View Tweet)

Popular Read: Little Effect with Multimodal Treatment of CMC1 Osteoarthritis https://t.co/6SnJYOK6nu https://t.co/ldTQRujshq

Links:

Dr. John Cush RheumNow ( View Tweet)
RNL 2021 - Future Therapies in RA: Dr. Roy Fleischmann https://t.co/icnRaUHo5k

Links:

Dr. John Cush RheumNow ( View Tweet)

Meet the #SLEEducatorsNetwork in this disease education series where leading rheumatologists and nephrologists share their perspectives on lupus nephritis. Sponsored by GSK US Medical Affairs https://t.co/H9BqP9bW4i https://t.co/VzS95UBJeo

Links:

Dr. John Cush RheumNow ( View Tweet)
News: Factors Associated with COVID-19 Deaths in Rheumatic Patients https://t.co/FzsINtpZEz https://t.co/QzuLZRKaZy

Links:

Dr. John Cush RheumNow ( View Tweet)
Levamisole, an anti-helminthic vet drug, is used as a colorless, odorless, adulterant to narcotics, cocaine, fentanyl, etc. Levamisole also causes ANCA+ Vasculitis (small to medium vessels), palpable purpura, agranulocytosis https://t.co/BKoDo2iemJ https://t.co/bSl0eYn0yO

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Live is now available for all--check out any panels you may have missed. https://t.co/jaisVc2kGt https://t.co/Z9m7V96g1g

Links:

Dr. John Cush RheumNow ( View Tweet)
Listen to Dr. Jack Cush review the news and journal reports from the past week on RheumNow. Our latest podcast is available for download on SoundCloud, Apple and Android carplay. https://t.co/FvmmOBAjC1 https://t.co/rrZO6jOlKt

Links:

Dr. John Cush RheumNow ( View Tweet)
Italian study of 1216 rheumatic pts on DMARDs, Biologics underwent HBV testing. They found HBV in 15.7% (chronic infection: 0.4%, resolved infection: 12.6%, anti-HBc positivity alone: 2.6%). HBV reactivation occurred in 6.2%. Only 1 acute hepatitis https://t.co/WofN4rqq6p

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021: Difficult, Refractory RA Dr. Maya Buch presents Difficult, Refractory RA at RheumNow Live 2021. https://t.co/YG8gBFVCod

Links:

Dr. John Cush RheumNow ( View Tweet)

×